You have 9 free searches left this month | for more free features.

ESCC

Showing 1 - 25 of 250

STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS

Esophageal Squamous Cell Carcinoma Trial in Anyang, Zhengzhou (AK104, nab-paclitaxel, carboplatin)

Not yet recruiting
  • Esophageal Squamous Cell Carcinoma
  • AK104, nab-paclitaxel, carboplatin
  • Anyang, Henan, China
  • +1 more
Jun 1, 2023

Esophagus Cancer Trial in Xiamen (Tislelizumab, Paclitaxel-albumin, Carboplatin)

Recruiting
  • Esophagus Cancer
  • Xiamen, Fujian, China
    ShanghaiZhongshan
Apr 8, 2023

Esophageal Squamous Cell Carcinoma (ESCC), PD-1 Inhibitors Trial in Zhengzhou (IBI110+Sintilimab)

Not yet recruiting
  • Esophageal Squamous Cell Carcinoma (ESCC)
  • PD-1 Inhibitors
  • Zhengzhou, Henan, China
    Feng Wang
Oct 9, 2023

Esophageal Squamous Cell Carcinoma, Oligometastatic Disease Trial in Beijing (Esophagectomy)

Active, not recruiting
  • Esophageal Squamous Cell Carcinoma
  • Oligometastatic Disease
  • Esophagectomy
  • Beijing, China
  • +1 more
Jul 11, 2023

Advanced Esophageal Squamous Cell Carcinoma Trial in Beijing, Xiamen, Xinxiang (Afatinib, Irinotecan)

Recruiting
  • Advanced Esophageal Squamous Cell Carcinoma
  • Beijing, China
  • +2 more
Apr 6, 2023

Esophageal Squamous Cell Carcinoma, Locally Advanced Carcinoma Trial in Nanjing (Tislelizumab, 5-FU, cis Platinum)

Recruiting
  • Esophageal Squamous Cell Carcinoma
  • Locally Advanced Carcinoma
  • Nanjing, Jiangsu, China
    Jiangsu Provincial People's Hospital
Jul 19, 2022

Esophageal Squamous Cell Carcinoma, Tislelizumab, Chemoradiation Trial in Nanjing (Tislelizumab, Paclitaxel, Carboplatin)

Recruiting
  • Esophageal Squamous Cell Carcinoma
  • +2 more
  • Nanjing, Jiangsu, China
    Jiangsu Cancer Institute & Hospital
May 24, 2022

Esophageal Squamous Cell Carcinoma Trial in Beijing (Pembrolizumab)

Recruiting
  • Esophageal Squamous Cell Carcinoma
  • Beijing, Beijing, China
    Cancer Institute and Hospital, Chinese Academy of Medical Scienc
Sep 13, 2022

Esophageal Squamous Cell Carcinoma by AJCC V8 Stage Trial (Radiotherapy, Toripalimab)

Not yet recruiting
  • Esophageal Squamous Cell Carcinoma by AJCC V8 Stage
  • (no location specified)
Mar 17, 2023

Primary Tumor Burden Score:A Novel Staging Parameter for ESCC

Completed
  • Neoplasm, Esophagus
  • Neoplasm, Squamous Cell
  • nCRT
  • (no location specified)
Apr 20, 2023

Metastatic Esophageal Squamous Cell Carcinoma Trial in Shanghai (Radiotherapy)

Recruiting
  • Metastatic Esophageal Squamous Cell Carcinoma
  • Radiotherapy
  • Shanghai, China
    Fudan University Shanghai cancer center
Feb 27, 2023

Index of Lymphadenectomy for Thoracic Escc

Completed
  • Esophageal Cancer
    • Chengdu, Sichuan, China
      Sichuan Cancer Hospital and Research Institute
    Nov 3, 2022

    NLR and Its Association With Efficacy of Immunochemotherapy in

    Recruiting
    • Esophageal Squamous Cell Carcinoma
    • +2 more
      • Guangzhou, Guangdong, China
        Guangdong Provincial People's Hospital
      Nov 10, 2023

      Recurrent or Metastatic Esophageal Squamous Cell Carcinoma Trial (SBRT, Cadonilimab)

      Not yet recruiting
      • Recurrent or Metastatic Esophageal Squamous Cell Carcinoma
      • (no location specified)
      Feb 8, 2023

      Locally Advanced Esophageal Squamous Cell Carcinoma Trial (Tiragolumab)

      Not yet recruiting
      • Locally Advanced Esophageal Squamous Cell Carcinoma
      • (no location specified)
      Feb 23, 2023

      Esophageal Squamous Cell Carcinoma, Esophageal Cancer, Metastatic Esophageal Squamous Cell Carcinoma Trial in Shanghai

      Recruiting
      • Esophageal Squamous Cell Carcinoma
      • +2 more
      • LDRT+CFRT
      • +2 more
      • Shanghai, China
      • +1 more
      Aug 3, 2023

      Esophageal Squamous Cell Carcinoma Trial (Combination (S095033 + paclitaxel))

      Not yet recruiting
      • Esophageal Squamous Cell Carcinoma
      • Combination (S095033 + paclitaxel)
      • (no location specified)
      Mar 28, 2022

      Esophageal Squamous Carcinoma, HER-2 Protein Overexpression Trial (RC48+PD-1+platinum-based)

      Not yet recruiting
      • Esophageal Squamous Carcinoma
      • HER-2 Protein Overexpression
      • (no location specified)
      Sep 24, 2023

      Esophageal Squamous Cell Carcinoma, Oligometastatic Disease Trial in Guangzhou (PD-1 combined with SBRT)

      Recruiting
      • Esophageal Squamous Cell Carcinoma
      • Oligometastatic Disease
      • PD-1 combined with SBRT
      • Guangzhou, Guangdong, China
        Mian Xi
      Dec 18, 2022

      Esophageal Cancer Trial in Tianjin (Arm A, Arm B)

      Not yet recruiting
      • Esophageal Cancer
      • Arm A
      • Arm B
      • Tianjin, Tianjin, China
        Tianjin Cancer Hospital
      Sep 24, 2023

      Locally Advanced Esophageal Squamous Cell Carcinoma Trial in Taipei (Nivolumab)

      Recruiting
      • Locally Advanced Esophageal Squamous Cell Carcinoma
      • Taipei, Taiwan
        National Taiwan University Hospital
      Nov 22, 2021

      Esophageal Squamous Cell Carcinoma Trial in Hangzhou (Cadonilimab combined Anlotinib)

      Recruiting
      • Esophageal Squamous Cell Carcinoma
      • Cadonilimab combined Anlotinib
      • Hangzhou, Zhejiang, China
        2nd Affiliated Hospital, School of Medicine, Zhejiang University
      Aug 6, 2023

      Esophageal Squamous Cell Carcinoma, Chemo Effect, Side Effect of Drug Trial in Nanjing (Consolidation chemo (4 courses),

      Recruiting
      • Esophageal Squamous Cell Carcinoma
      • +2 more
      • Consolidation chemotherapy (4 courses)
      • Concurrent chemotherapy (2 courses)
      • Nanjing, Jiangsu, China
        The First Affiliated Hospital of Nanjing Medical University
      Mar 16, 2023

      ctDNA-MRD in Predicting Efficacy of Esophageal Squamous Cell

      Not yet recruiting
      • Squamous Cell Carcinoma of Esophagus
        • (no location specified)
        Feb 25, 2023